Aduro Completes $137 Million Initial Public Offering

Palo Alto– April 30, 2015 – Cooley advised Aduro Biotech, Inc. on its $137 million initial public offering. Aduro is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company trades on The NASDAQ Global Market under the symbol "ADRO." Aduro also raised an additional $25 million in a private placement with Novartis Institutes for BioMedical Research, Inc., which closed concurrently with the offering.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Barbara Kosacz Partner, Palo Alto
Michael Tenta Partner, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Renee Deming Retired Partner, Palo Alto
Lesse Castleberry Senior Counsel, New York
Jennifer Raab Associate, Palo Alto
Bill Christiansen Partner, Seattle
Carlton Fleming Partner, Palo Alto
Phil Mitchell Partner, New York
Peter Mandel Associate, San Francisco
Robert Phillips Partner, San Francisco